In late 2025, Meituan, a leading lifestyle super app in China, introduced its Xiaomei AI agent, which redefines the concept of digital assistance. Unlike traditional chatbots, Xiaomei acts as an orchestrator and execution agent, allowing users to delegate tasks with remarkable ease. Imagine simply saying, “Order my usual lunch, but deliver it 20 minutes later today,” and having the AI understand your preferences and execute the order without any screen interaction.

In a significant development for the tech industry, Factory has recently achieved a staggering $1.5 billion valuation after securing $150 million in funding. This startup is poised to revolutionize AI-assisted coding for enterprise engineering teams, a sector that has become increasingly competitive with players like Anthropic and Cursor already in the mix. Factory’s unique approach lies in its ability to seamlessly switch between various foundation models, setting it apart from its competitors.

Novo Nordisk’s recent partnership with OpenAI marks a significant leap forward in the realm of drug discovery, promising to expedite the development of innovative treatments for obesity and diabetes. By harnessing the power of artificial intelligence, Novo aims to analyze complex datasets more effectively, identify potential new drugs, and streamline the transition from research to patient care. CEO Mike Doustdar emphasized the urgency of this initiative, noting that millions of individuals are in need of new therapies that could transform their lives.